<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04887870</url>
  </required_header>
  <id_info>
    <org_study_id>516-014</org_study_id>
    <nct_id>NCT04887870</nct_id>
  </id_info>
  <brief_title>Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study</brief_title>
  <official_title>A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirati Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mirati Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Study of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Advanced&#xD;
      or Metastatic Malignancies&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that inhibits&#xD;
      several closely related RTKs including the TAM family (Tyro3/Axl/MERTK), VEGFR2, KIT, and&#xD;
      MET.&#xD;
&#xD;
      The current study is designed to allow continued access to sitravatinib and to evaluate the&#xD;
      safety and tolerability of sitravatinib alone or in combination with other anticancer&#xD;
      therapies in patients who are deriving clinical benefit in a previous parent clinical trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 30, 2021</start_date>
  <completion_date type="Anticipated">February 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of subjects experiencing treatment-related AEs.</measure>
    <time_frame>24 Months</time_frame>
    <description>Frequency of subjects experiencing treatment-related AEs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to clinical or radiographic progression on study.</measure>
    <time_frame>24 Months</time_frame>
    <description>Time to clinical or radiographic progression on study.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Advanced or Metastatic Solid Malignancies</condition>
  <arm_group>
    <arm_group_label>Phase 2/3: Open label extension of parent study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The current study is designed to allow continued access to sitravatinib and to evaluate the safety and tolerability of sitravatinib alone or in combination with other anticancer therapies in patients who are deriving clinical benefit in a previous parent clinical trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitravatinib</intervention_name>
    <description>Sitravatinib is a small molecule inhibitor of recepor tyrosine kinases.</description>
    <arm_group_label>Phase 2/3: Open label extension of parent study</arm_group_label>
    <other_name>MGCD516</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody</description>
    <arm_group_label>Phase 2/3: Open label extension of parent study</arm_group_label>
    <other_name>OPDIVO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody</description>
    <arm_group_label>Phase 2/3: Open label extension of parent study</arm_group_label>
    <other_name>KEYTRUDA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enfortumab Vedotin-Ejfv</intervention_name>
    <description>Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)</description>
    <arm_group_label>Phase 2/3: Open label extension of parent study</arm_group_label>
    <other_name>PADCEV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody</description>
    <arm_group_label>Phase 2/3: Open label extension of parent study</arm_group_label>
    <other_name>YERVOY</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Currently receiving sitravatinib single- agent or in combination with other&#xD;
             therapeutic agent(s) in another Mirati- sponsored protocol&#xD;
&#xD;
          -  Currently tolerating the treatment regimen in the parent protocol&#xD;
&#xD;
          -  Experiencing clinical benefit with or without prior radiographic progression from the&#xD;
             treatment regimen in the parent protocol in the opinion of the investigator and the&#xD;
             investigator determines that continuing treatment is in the patient's best interest&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected presence of other cancer&#xD;
&#xD;
          -  Other life- threatening illness or organ system dysfunction compromising safety&#xD;
             evaluation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronald Shazer, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mirati Therapeutics Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mirati Therapeutics Study Locator Services</last_name>
    <phone>18448935530</phone>
    <email>miratistudylocator@emergingmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beverly Hills Cancer Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leena Gandhi, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Health Clinics and Surgery Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manish Patel, DO</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Wexner Medical Center - Thoracic Oncology Clinic</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai He, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Denison Cancer Center</name>
      <address>
        <city>Denison</city>
        <state>Texas</state>
        <zip>75020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tammy E Roque, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Sommerhalder, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>May 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 14, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

